Sanofi could have two new drugs on the market for the treatment of multiple sclerosis by the end of the year. The company announced June 12 that its Genzyme subsidiary has submitted regulatory filings for Lemtrada (alemtuzumab) for the treatment of relapsing forms of MS in the U.S. and Europe. In the U.S., the company is seeking a six-month priority review, which would position the drug for a potential approval and launch before the end of the year.
Lemtrada is one of two MS drugs Sanofi is planning to launch in the near-term with an eye on building...